DARE to PLAY™ (Sildenafil Cream)

About Daré Bioscience

Daré Bioscience is a mission-driven biotech dedicated to closing the care gap in the historically underfunded field of women's health. Its strategy centers on developing and commercializing novel, often non-hormonal products through rigorous clinical development, with its first FDA-approved product, DARE to PLAY™ (Sildenafil Cream), now available via telehealth. The company's pipeline is broad, targeting key life stages from contraception to menopause, and is supported by strategic government funding, including a $10 million ARPA-H contract for its HPV program.

About Dare Bioscience

Daré Bioscience is a mission-driven, clinical-stage biotech pioneering evidence-based therapeutics exclusively for women's health. The company has achieved a key milestone with the commercial launch of DARE to PLAY™ Sildenafil Cream, the first FDA-approved topical treatment for female sexual arousal disorder, while advancing a broad pipeline including hormone-free contraception and a novel HPV treatment. Its strategy centers on leveraging localized drug delivery platforms to improve safety and efficacy, targeting large, underserved markets with high unmet need. Operating as a lean, virtual R&D organization, Daré partners with CROs and leverages non-dilutive funding to advance its programs toward commercialization.

Therapeutic Areas